Because human bone marrow ( BM ) CD@ + stem cells home into damaged tissue and may play an important role in tissue repair , this pilot clinical trial explored the safety and feasibility of intravitreal autologous CD@ + BM cells as potential therapy for ischemic or degenerative retinal conditions .